BioSpace News Archive

Ocuphire Pharma, Inc. announced that clinical data from its ZETA-1 trial evaluating APX3330 in diabetic retinopathy on a validated binocular person-level scale was presented yesterday at the Association for Research in Vision and Ophthalmology Annual Meeting, taking place May 5-9, 2024 in Seattle, Washington.

BioAtla, Inc. announced that the U.S. Food and Drug Administration has cleared its investigational new drug application to evaluate BA3361 antibody drug conjugate for the treatment of multiple tumor types.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the clearance of its Investigational New Drug application (“IND”) by the U.S. Food and Drug Administration for VYN202, an oral BD2-selective BET inhibitor.

Belite Bio, Inc. (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced additional findings from the 24-month Phase 2 study of Tinlarebant in adolescent Stargardt disease (STGD1) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the sale of the first SRT-100 Vision™ system in Asia, to Far Eastern Memorial Hospital in Taiwan.

BioStem Technologies Inc. announced that the United States Patent and Trademark Office has granted the Company’s request for Prioritized Examination for its application for U.S. Patent 18/290,914.

AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024.

ZygoFix Ltd. a portfolio company of The Trendlines Group Ltd. (“Trendlines”) announced that it received regulatory clearance from the United States Food and Drug Administration (FDA clearance) for its zLOCK Lumbar Facet Fixation System.

Congruence Therapeutics, a leading computationally-driven biotechnology company developing a pipeline of novel small molecules for diseases with significant unmet medical need, announced the appointment of Michael D. Harvey, Ph.D. as Chief Development Officer.

Regulus Therapeutics Inc. today announced, after review of all available safety data, the Company initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three months.